Navigation Links
Industry leaders join together for historic Accelerating Cancer Cures Research Symposium
Date:3/6/2012

New York, NY (March 5, 2012) Today, the Damon Runyon Cancer Research Foundation held its first Accelerating Cancer Cures Research Symposium, focused on rebuilding the ranks of physician-scientists specially trained to translate laboratory discoveries into new cancer therapies. The event, held at Pfizer Inc headquarters, brought together academic scientists and other leading pharmaceutical companies, including Eli Lilly and Company, Celgene, Genentech, Merck, and Millennium: The Takeda Oncology Company.

The symposium is the first of its kind since Damon Runyon, a New York-based foundation, launched its Accelerating Cancer Cures program in June 2011. Accelerating Cancer Cures is a five-year, multi-million dollar project that will train a new generation of exceptional clinical investigators capable of translating the latest scientific discoveries into new diagnostics and therapeutics for cancer patients. The initiative also eliminates barriers to progress by fostering communication and collaboration between academia and industry. It is supported by some of the world's leading companies and The Pharmaceutical Research and Manufacturers of America (PhRMA).

"We risk losing tremendous ground in our effort to find cures for cancer if we cannot attract new talent and new ideas to clinical research," said Damon Runyon Cancer Research Foundation President and CEO Lorraine Egan when the program launched. "Our best hope for crucial breakthroughs to prevent, diagnose and treat cancer lies with the committed young scientists who will be able to pursue critical translational research thanks to this effort."

Scientists from the nation's leading research institutions, including the Dana-Farber Cancer Institute, Fred Hutchinson Cancer Research Center, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, and the University of North Carolina, Chapel Hill, traveled to New York to attend.

Pfizer Vice President Jamey R. Skillings, MD, MSc, MBA, led a discussion on targeted therapies for cancer, and Celgene Vice President Rajesh Chopra, MD, PhD, chaired a session on immunotherapies. They were joined by twenty Damon Runyon-funded scientists.

The day ended with a panel discussion, moderated by Damon Runyon Chief Scientific Officer Yung S. Lie, PhD, about navigating the boundaries between industry and academia and overcoming barriers to collaboration and translational research.


'/>"/>

Contact: Todd Brogan
todd.brogan@damonrunyon.org
212-455-0552
Damon Runyon Cancer Research Foundation
Source:Eurekalert

Related medicine news :

1. ClearWay Minnesota(SM) Shines a Spotlight on a Reinvented Tobacco Industry
2. Industry Recognizes the Regence Health Engine for Excellence in Creativity, Innovation and Information
3. Chocolate Industry Leaders Sign Agreement, Align on Path Towards Increasing Consumer Availability & Consistency of Beneficial Cocoa Flavanols
4. San Diego State University and BIOCOM Institute Receive $4.95 Million Grant: The BRIDGE Project, Linking Education to Employment in San Diegos Life Sciences Industry
5. Language Service Leader Expands to Meet Booming, Global Industry Demand.
6. Vestara and EXP Pharmaceutical Services Corp. Announce Partnership Making Available Industry's Only Automated Pharmaceutical Waste Management Solution to over 5,000 U.S. Hospitals
7. Pelosi, Senior Democrats Remarks at News Conference on Repealing Health Insurance Industry Anti-Trust Exemption
8. Researchers at No. 1-Ranked U.S. Childrens Hospital Work with Industry to Develop a Child Crash Dummy thats More True-to-Life
9. Innovative Medical Alert Device Sets a New Standard in PERS Industry
10. Dairy Industry Raises a Glass of Milk to Lets Move! Campaign
11. LG Electronics Provides a Dose of HD for the Healthcare Industry at HIMSS 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... in Dallas, Texas, is condemning "scam operations" carried out by unethical locksmith companies ... these scam operations to a halt. According to Texas Premier Locksmith, these fraudulent ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... The medical ... holidays and winter seasons. One major study analyzing heart attacks among 138,602 people ... August of a given year. We would all agree of course–no time of year ...
(Date:12/7/2016)... Ohio (PRWEB) , ... December 07, 2016 , ... ... in the 2016 BOC Business Brilliance Awards under the Best New Product Launch ... and results achieved through user experience. , BOC Global Events & Training Group ...
(Date:12/7/2016)... ... 2016 , ... Maureen McLaughlin, LA.c., a certified acupuncturist, is ... Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility patients to ... their family building goals. Acupuncture helps fertility patients by supporting the ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a brief ... the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation of ... can for this country. , Nancy attributes her patriotic nature to her WWII veteran ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)...  Lannett Company, Inc. (NYSE: LCI ) today announced ... Prescription for Success Healthcare Conference on December 14, 2016 at 9:20 ... York City . In addition, the company will ... 4 th Annual Boston Healthcare Conference taking place on December ... ...
(Date:12/6/2016)... CONCORD, Mass. , Dec. 6, 2016  Alopexx ... of DI-Leu16-IL2, a recombinant antibody fusion protein (immunocytokine) composed ... antibody recognizes the same target on B cells as ... and cytokine components but is also involved in tumor ... an anti-cancer vaccine effect. The results of the study ...
(Date:12/6/2016)... , Dec. 6, 2016 Diabetes & Obesity ... diabetes and obesity disease cluster is currently dominated by ... type 2 diabetes mellitus (T2DM), and the majority of ... of products, is attributable to these indications. While products ... market presence, there are a large number of these ...
Breaking Medicine Technology: